Katherine Stueland, the Chief Executive Officer of GeneDx Holdings Corp. (NASDAQ:WGS), has sold a significant portion of her holdings in the company. According to a recent filing, Stueland sold shares totaling approximately $3.2 million. The transactions, conducted on November 15 and 18, involved a series of sales with prices ranging from $66.60 to $74.34 per share.
The sales were executed under a Rule 10b5-1 trading plan, which was adopted by Stueland on August 16, 2024. Following these transactions, Stueland retains direct ownership of 60,011 shares of GeneDx, reflecting her continued stake in the company.
GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is based in Stamford, Connecticut, and operates in the health services sector. The company continues to focus on expanding its offerings in genetic testing and related health services.
In other recent news, GeneDx, a key player in genomic testing, has reported a substantial year-over-year revenue increase of 52% for the third quarter of 2024, reaching a noteworthy $76 million. This marks the first instance of profitability for the company, signifying a significant milestone in its financial trajectory. The company's strategic growth in the pediatric outpatient market and advancements in genomic testing offerings were highlighted in the earnings call. GeneDx also raised its full-year 2024 revenue guidance to an estimated $284-$290 million.
A promising partnership with Epic is anticipated to integrate genomic testing into major health systems in 2025. GeneDx has sequenced over 700,000 clinical exomes and genomes, capturing a significant 80% of the U.S. exome market. On the other hand, the company reported a decrease in prior period collections to $6.3 million, down from $7 million.
GeneDx is set to enhance its offerings in the NICU setting and increase genetic testing utilization among pediatric neurologists. Furthermore, the company is making strategic investments to support profitable growth and innovation in exome and genome testing. These recent developments indicate a positive outlook for GeneDx, as it continues to dominate the genomic testing market.
InvestingPro Insights
The recent stock sale by GeneDx Holdings Corp.'s CEO Katherine Stueland comes amid a period of significant volatility and growth for the company. According to InvestingPro data, GeneDx has experienced a remarkable 5015.11% price total return over the past year, with a particularly strong 226.75% return in the last six months. This impressive performance aligns with an InvestingPro Tip indicating that the stock has seen a "large price uptick over the last six months."
Despite the recent insider sale, analysts remain optimistic about GeneDx's future. An InvestingPro Tip reveals that four analysts have revised their earnings upwards for the upcoming period, suggesting potential growth ahead. However, it's worth noting that the company is not currently profitable, with a negative operating income of $54.65 million in the last twelve months.
GeneDx's market capitalization stands at $1.96 billion, reflecting its significant presence in the genetic testing and health services sector. The company's revenue growth is noteworthy, with a 29.41% increase over the last twelve months and an even more impressive 44.22% growth in the most recent quarter.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for GeneDx, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.